Shane Thomas Gleason Sells 22,778 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 22,778 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $1.01, for a total transaction of $23,005.78. Following the completion of the sale, the insider owned 1,053,882 shares of the company’s stock, valued at approximately $1,064,420.82. The trade was a 2.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

InspireMD Stock Down 2.9%

NSPR stock opened at $1.00 on Friday. InspireMD, Inc. has a 12-month low of $0.97 and a 12-month high of $2.93. The company has a market cap of $46.84 million, a price-to-earnings ratio of -1.33 and a beta of 0.82. The company has a 50 day moving average of $1.38 and a two-hundred day moving average of $1.66.

Wall Street Analyst Weigh In

A number of research firms have issued reports on NSPR. Lake Street Capital set a $4.00 target price on shares of InspireMD in a research report on Monday, May 4th. Piper Sandler restated an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Maxim Group began coverage on shares of InspireMD in a report on Monday, February 2nd. They set a “buy” rating and a $6.00 price target on the stock. Finally, Loop Capital set a $5.00 price target on shares of InspireMD in a report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, InspireMD currently has a consensus rating of “Buy” and an average price target of $4.50.

Key Stories Impacting InspireMD

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
• Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
• Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC bought a new position in shares of InspireMD during the 1st quarter valued at $29,000. Virtu Financial LLC bought a new position in shares of InspireMD during the 4th quarter valued at $31,000. XTX Topco Ltd bought a new position in shares of InspireMD during the 4th quarter valued at $30,000. Orbimed Advisors LLC raised its holdings in shares of InspireMD by 46.9% during the 4th quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock valued at $5,577,000 after purchasing an additional 1,000,000 shares in the last quarter. Finally, Essex Investment Management Co. LLC bought a new position in shares of InspireMD during the 4th quarter valued at $203,000. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.